Cancer Screening Market Size, Share, Growth, and Industry Analysis by Type (Laboratory Tests, Genetic Tests, Imaging, Endoscopy and Biopsy) By Application (Colorectal Cancer, Cervical Cancer, Breast Cancer, Lung Cancer, Prostate Cancer, Skin Cancer, Blood Cancer, Kidney Cancer, Liver Cancer, Pancreatic Cancer and Ovarian Cancer) Regional Forecast From 2025 To 2033
Trending Insights

Global Leaders in Strategy and Innovation Rely on Our Expertise to Seize Growth Opportunities

Our Research is the Cornerstone of 1000 Firms to Stay in the Lead

1000 Top Companies Partner with Us to Explore Fresh Revenue Channels
CANCER SCREENING MARKET OVERVIEW
The global Cancer Screening Market, valued at USD 201.27 billion in 2024, is projected to grow steadily to USD 216.26 billion in 2025 and reach USD 384.27 billion by 2033, maintaining a CAGR of 7.45% from 2025 to 2033.
The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market's growth and demand returning to pre- pandemic levels once the pandemic is over.
The cancer screening market refers to the industry of medical devices, tests, and services that are used to screen for cancer in patients. The market includes various types of cancer screening tests, such as blood tests, imaging tests, and genetic tests. The cancer screening market has been growing in recent years due to increased awareness of cancer and its early detection, as well as advancements in medical technology. The market is also being driven by the aging population, as cancer incidence tends to increase with age.
The cancer screening market is expected to continue to grow in the coming years, driven by increasing cancer incidence rates, a growing population, and advancements in technology. However, the market may also face challenges, such as regulatory hurdles and competition from alternative screening methods.
COVID-19 IMPACT
Reduction in Healthcare Budgets to Limit the Market Demands
Due to the pandemic, many people have been hesitant to visit healthcare facilities for routine screenings, including cancer screenings. As a result, there has been a delay in cancer diagnoses, which can impact the demand for cancer screening products. The pandemic has put a strain on healthcare budgets, with many countries diverting resources towards managing the pandemic. This can impact the availability of cancer screening tests, especially in low-income countries.
LATEST TRENDS
Increasing Use of Liquid Biopsy to Augment the Market Growth
One of the latest trends in cancer screening is the increasing use of liquid biopsy. Liquid biopsy is a minimally invasive test that analyzes a patient's blood sample for circulating tumor cells, DNA, and other biomarkers that can indicate the presence of cancer. Compared to traditional biopsy methods, liquid biopsy is less invasive, faster, and can be used to monitor cancer progression and treatment response. Another trend in cancer screening is the use of artificial intelligence (AI) and machine learning (ML) algorithms to improve cancer detection rates. These algorithms can analyze large amounts of patient data, including medical images, genetic information, and patient histories, to identify patterns and predict which patients are most likely to develop cancer.
CANCER SCREENING MARKET SEGMENTATION
By Type Analysis
By type, market is segmented into laboratory tests, genetic tests, imaging, endoscopy and biopsy. The laboratory tests type segment will dominate the market in the coming years.
By Application Analysis
Based on applications, the market is classified into colorectal cancer, cervical cancer, breast cancer, lung cancer, prostate cancer, skin cancer, blood cancer, kidney cancer, liver cancer, pancreatic cancer and ovarian cancer. The colorectal cancer segment will lead the global share through 2033.
DRIVING FACTORS
Increasing Prevalence of Cancer and Technological Advancements to Push the Market
The rising incidence of cancer globally has led to a growing demand for cancer screening tests. There is increasing awareness among the public and healthcare professionals about the importance of early detection of cancer, which has led to an increase in demand for cancer screening tests. Advances in technology have led to the development of more accurate and efficient cancer screening tests, which has increased their adoption.
Aging Population to Boost the Market Growth
Governments around the world are taking initiatives to promote cancer screening programs, which has boosted the growth of the cancer screening market. The aging population is more prone to developing cancer, which has led to an increase in demand for cancer screening tests. The rise in healthcare expenditure globally has led to increased investment in the development of new cancer screening tests and technologies. The growing prevalence of risk factors such as tobacco use, obesity, and sedentary lifestyles has led to an increase in the incidence of cancer, which has further boosted the demand for cancer screening tests.
RESTRAINING FACTORS
Lack of Awareness and High Cost of Screening to Slow the Market Growth
In some areas, access to healthcare services and cancer screening tests may be limited, which can restrict the growth of the cancer screening market. Cancer screening tests can be expensive, especially for those without health insurance or those with high deductibles. This can deter some people from getting screened and limit the market potential. Some individuals may be hesitant to undergo cancer screening tests due to the fear and anxiety associated with potential diagnoses. This can limit the market potential for cancer screening tests. False positives can occur with some cancer screening tests, which can lead to unnecessary medical procedures and expenses. This can also lead to a lack of trust in the accuracy of screening tests.
-
Request a Free sample to learn more about this report
CANCER SCREENING MARKET REGIONAL INSIGHTS
North American Market to Grow Exponentially with the Forecasted Period
North America is currently the largest market for cancer screening due to the increasing prevalence of cancer, high healthcare spending, and the presence of advanced healthcare infrastructure. The United States is the major contributor to the North American market due to the rising incidence of cancer and the presence of well-established healthcare facilities.
The Asia Pacific region is expected to grow at the fastest rate during the forecast period, primarily due to the increasing prevalence of cancer, the rising geriatric population, and improving healthcare infrastructure. China and India are expected to be the major contributors to the Asia Pacific market due to their large population base and increasing healthcare expenditure.
KEY INDUSTRY PLAYERS
Key Players Focus on Partnerships to Gain a Competitive Advantage
Prominent market players are making collaborative efforts by partnering with other companies to stay ahead in the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolio.
List of Top Cancer Screening Companies
- Fujirebio Diagnostics, Inc. (Japan)
- Alere (U.S.)
- Immunostics (U.S.)
- Oncohealth Corporation (U.S.)
- Sysmex (Japan)
- Xeptagen (Italy)
- Orion Genomics (U.S.)
- Abbott (U.S.)
- Qiagen (Germany)
- Quest Diagnostics (U.S.)
- Biohit Oyj (Finland)
- Hologic, Inc. (U.S.)
- Clarient (U.S.)
- Femasys, Inc. (U.S.)
- BioMerieux (France)
- Roche (Switzerland)
- DiaSorin (Italy)
- Beckman Coulter (U.S.)
- Siemens (Germany)
REPORT COVERAGE
The market research study examines the worldwide market in detail, focusing on important elements such as leading players, product/services or type, and leading end-use applications. Aside from that, the research analyses major advancements and provides insights into lighting market trends. In addition to the causes indicated above, the paper includes a number of other factors that have contributed to recent growth.
Attributes | Details |
---|---|
Market Size Value In |
US$ 201.27 Billion in 2024 |
Market Size Value By |
US$ 384.27 Billion by 2033 |
Growth Rate |
CAGR of 7.45% from 2025to2033 |
Forecast Period |
2025-2033 |
Base Year |
2024 |
Historical Data Available |
Yes |
Regional Scope |
Global |
Segments Covered |
|
By Type
|
|
By Application
|
FAQs
The global cancer screening market are expected to touch USD 384.27 billion by 2033.
The cancer screening market is expected to exhibit a CAGR of 7.45% by 2033.
Increasing prevalence of cancer, technological advancements and aging population are some of the driving factors of the cancer screening market.
North America is the leading region in the market for cancer screening.
Fujirebio Diagnostics, Inc., Oncohealth Corporation, Orion Genomics Quest Diagnostics and Beckman Coulter are some of the leading players in the cancer screening market.